H. Lee Moffitt Cancer Center and Research Institute

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, H. Lee Moffitt Cancer Center and Research Institute sits in the top decile of US sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count).

502 total trials 82 currently recruiting 280 completed early-phase tilt top decile by trial count

H. Lee Moffitt Cancer Center and Research Institute: 502 sponsored US clinical trials, 82 recruiting.

H. Lee Moffitt Cancer Center and Research Institute sponsors 502 registered US clinical trials on ClinicalTrials.gov, 82 of them currently recruiting, and 280 completed. 5 of these trials are in Phase 3-4 (later-stage) and 335 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.

Top-decile sponsor footprint

H. Lee Moffitt Cancer Center and Research Institute ranks in the top decile of sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 43/100

280 of 344 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

What is open in the H. Lee Moffitt Cancer Center and Research Institute pipeline

82 recruiting of 502 indexed (16% open); 280 completed (56%).

Phase mix: 5 late (III/IV) vs 335 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

H. Lee Moffitt Cancer Center and Research Institute: open-pipeline peers nationwide

Peers matched on 502 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 0%5%10%15%20% Total trials Recruiting share H. Lee Moffitt Cancer Center and Research InstituteNational Heart, Lung, and Blood Institute (NHLBI)Gilead SciencesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Boehringer IngelheimCase Western Reserve UniversityDrexel UniversityAtlantic Health SystemBioMarin Pharmaceutical
H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 502 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this H. Lee Moffitt Cancer Center and Research Institute page

502 registered trials is a research-attention snapshot, not an endorsement of H. Lee Moffitt Cancer Center and Research Institute or any single study.

  • 82 of H. Lee Moffitt Cancer Center and Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition H. Lee Moffitt Cancer Center and Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. H. Lee Moffitt Cancer Center and Research Institute pipeline card: 502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.